Last updated: 2026-11-14 03:51:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Vertex Pharmaceuticals Inc. (VRTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $538.68, with a market capitalization of $137.57B and a P/E ratio of 34.60. Over the past 52 weeks, its price has ranged from $412.27 to $568.67. This page covers its latest market performance, valuation, price trends and company information.
$137.57B | |
$542.12 | |
$547.62 | |
$536.32 | |
$542.62 | |
487.09K | |
1.23M | |
34.60 | |
$568.67 | |
$412.27 | |
-- | |
12-31 |
Vertex Pharmaceuticals Inc. (VRTX) last closed at $538.68 as of 2026-11-14 00:56:00, down 0.75% ($4.08) from the previous close of $542.62.
During the latest regular trading session, VRTX traded between $536.32 and $547.62, with a volume of 487.09K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Vertex Pharmaceuticals Inc. (VRTX) moved from $542.50 to $538.68, representing a decline of 0.70% ($3.82).
The stock traded between $531.53 and $557.85 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.18 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80.8%
VRTX is currently trading at $538.68, placing it 80.8% of the way from its 52-week low of $412.27 to its 52-week high of $568.67. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6,400 |
| CEO | Reshma Kewalramani |
| Founded | 1989 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Vertex Pharmaceuticals Inc. and VRTX stock.
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.32% on an annualized basis producing an average annual return of 19.42%. Currently, Vertex Pharmaceuticals has a market
Vertex Pharmaceuticals has been heavily searched on Zacks.com and has outperformed the broader market with a +12.9% return over the past month. However, the company faces headwinds with declining earnings estimates and a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the market. The stock is trading at a premium valuation (Grade D) relative to peers, with mixed earnings surprise history.
Vertex released its 2026 CompOps Index showing that enterprises with indirect tax as a standing board item are four times less likely to have errors identified externally and nearly twice as likely to respond to tax-authority notices within five business days. Only 16% of enterprises currently have indirect tax as a standing board item, while 43% only discuss it when problems arise. The study also found that enterprises with board-level tax discussions are more likely to deploy AI autonomously in tax workflows (54% vs. 21%) and maintain better regulatory compliance.
Eligible investors can buy real shares of Vertex Pharmaceuticals Inc. (VRTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to VRTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between VRTX shares and USD.
VRTX Shares to USD
1.00 VRTX shares = 538.68 USD
Calculations are estimates based on the latest available price and are for reference only.
